Ix Biopharma Ltd. · SGX:42C
Ix Biopharma — 33rd CITIC Securities International Investor Forum 2026
16 slides from Ix Biopharma's conference presentation, Sep 23, 2026
Slide 1: Corporate Presentation – 33rd CITIC Securities Int'l Investor Forum
Corporate Presentation 33rd CITIC Securities Int’l Investor Forum Wednesday, 23 September 2026 For Release
Slide 2: Disclaimer
Disclaimer The information in this presentation has not been independently verified. This presentation is strictly private & confidential and is meant solely for your information only. Nothing in this presentation is or shall be considered to be an offer for the solicitation, sale or subscription of
Slide 3: Company Overview
Company Overview Specialty pharmaceutical company with Multi-drug platform delivery 1 expertise in drug delivery systems 2 technology, comprising patented matrix ✓ Listed on SGX Catalist in July 2015 formulation and proprietary freeze-dry Who ✓ Developed novel drug delivery platform Platform manufac
Slide 4: Unlocking Value
Unlocking Value May’26 Sep’26 Consumer Business Restructuring US Govt Declares 0.6 Military Emergency June’26 Nov’25 Feb’26 Relocate FD from AU to US JV with OSL Compounding 503B 1. DoD Contract Awarded @ US$41M 2. S$15M Capital Raised @ S$0.198 0.4 Oct’25 S$6.7M Capital Raised @ S$0.10 0.2 0.0 Oct
Slide 5: 2 Business Segments
2 Business Segments iX Biopharma Ltd Pharmaceuticals Consumer Business • Wafermine Asset • ~ 40 repurposed sublingual formulations, • Longevity nutraceuticals: NAD, GSH including hormones & peptides 5
Slide 6: Pharmaceuticals
PHARMACEUTICALS 6
Slide 7: Pharmaceutical Pipeline
Pharmaceutical Pipeline 40+ pharmaceutical products under development – Some highlights: Wafermine (Ketamine) – Pain/Depression Small Wafesil (Sildenafil) – Male Erectile Dysfunction Molecules BnoX (Buprenorphine) – Pain/Opioid Use Disorder iXB 323 (Testosterone) – Hormone Replacement Therapy iXB 32
Slide 8: Wafermine for Acute, Moderate-to-Severe Pain
Wafermine for Acute, Moderate-to-Severe Pain Wafermine • Developed under FDA 505b(2) for acute, moderate-to-severe pain • DoD to provide ~US$41M funding for P3 Studies & EUA o Strong validation of iX’s WaferiX Sublingual Technology o Funding derisks P3 study program; no The world’s first sublingual
Slide 9: Military Emergency Pathway Open
Military Emergency Pathway Open Wafermine reaches final regulatory step Pending EUA submission for approval 2019 Feb’26 Jul’26 Aug’26 End of Phase 2 $41M Secretary of War Secretary of HHS meeting cleared DoD award issues Determination signs Declaration with US FDA Funds Wafermine Phase 3 Military em
Slide 10: Big Pharma is All In!
Big Pharma is All In! The Problem Wafermine is Ready2 with Pain1 Driven by the opioid crisis, chronic pain epidemic, and increasing regulatory support for non-opioid pain therapies, the non-opioid pain market is one of pharma's fastest-growing segments 80M Opioid Crisis Response The Non-Opioids Prev
Slide 11: Consumer Business
CONSUMER BUSINESS via Expansion into the US Market
Slide 12: Current Business Segments
Current Business Segments iX Biopharma Ltd Pharmaceuticals Consumer Business • Wafermine Asset • ~ 40 repurposed sublingual formulations, • Longevity nutraceuticals: NAD, GSH including hormones & peptides 12
Slide 13: Restructuring Consumer Business
Restructuring Consumer Business • Restructure & transfer all consumer related businesses to a Newco: Ligo Pharma iX Biopharma Ltd Pharmaceuticals Consumer Business (Ligo Pharma) • Longevity nutraceuticals: NAD, GSH • Wafermine Asset • Compounding Pharmacy 503B/A • JV with OSL to provide immediate mo
Slide 14: US Compounding Pharmacy
US Compounding Pharmacy Compounding Pharmacies custom-make medications for patients or hospitals when Expansion into the compounding market is a strategic standard drugs do not work or are not available accelerator for revenue, data and market validation 503A 503B 01 Immediate Monetization: Commerci
Slide 15: Summary
SUMMARY 15
Slide 16: WaferiX Platform - Two Growth Engines
WaferiX Platform - Two Growth Engines Patented & Proprietary Sublingual Wafer Platform A freeze-dried oral wafer that dissolves under the tongue • High barrier to entry around the sublingual wafer platform 1) Rapid onset of action • Validated by the US Department of Defense 2) Higher bioavailability
iX Biopharma — 33rd CITIC Securities International Investor Forum 2026 on 6ix